Stock comparison
Guardian Pharmacy Services
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GRDN
Guardian Pharmacy Services
Market cap
$2.44B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GRDN | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 54C | 75B | IDXX |
| Benjamin Graham | 62D | 80A | IDXX |
| Philip Fisher | 57C | 75B | IDXX |
| Peter Lynch | 60C | 71B | IDXX |
| Joel Greenblatt | 61C | 83C | IDXX |
| Charlie Munger | 47D | 87A | IDXX |
| Terry Smith | 52C | 84A | IDXX |
Side-by-side metrics
| Metric | GRDN | IDXX |
|---|---|---|
| Market cap | $2.44B | $44.12B |
| P/E (TTM) | 42.7x | 39.0x |
| EV/EBIT | 30.8x | 31.6x |
| ROIC (TTM) | 20.71% | 40.66% |
| Gross margin | 20.93% | 62.05% |
| Net margin | 3.64% | 24.63% |
| Revenue CAGR 5y | 16.29% | 7.56% |
| EPS CAGR 5y | 30.79% | 10.79% |
| Debt / Equity | 0.2x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GRDN leads on
- Debt / Equity0.2xvs 0.7x+76%
- EPS CAGR 5y30.79%vs 10.79%+65%
- Revenue CAGR 5y16.29%vs 7.56%+54%
IDXX leads on
- Market cap$44.12Bvs $2.44B+94%
- Net margin24.63%vs 3.64%+85%
- Gross margin62.05%vs 20.93%+66%
- ROIC (TTM)40.66%vs 20.71%+49%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.